- Home
- PRME vs SIBN Comparison
PRME vs SIBN Comparison
Compare PRME & SIBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | SIBN |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.1M | 606.1M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PRME | SIBN |
|---|---|---|
| Price | $4.01 | $18.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $9.31 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 3.8M | 627.2K |
| Earning Date | 11-07-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,977,000.00 | ★ $193,578,000.00 |
| Revenue This Year | $111.80 | $21.44 |
| Revenue Next Year | N/A | $15.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 647.13 | 23.27 |
| 52 Week Low | $1.11 | $12.50 |
| 52 Week High | $6.94 | $20.05 |
Technical Indicators
Market Signals| Indicator | PRME | SIBN |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 51.90 |
| Support Level | $3.95 | $18.99 |
| Resistance Level | $4.42 | $19.44 |
| Average True Range (ATR) | 0.31 | 0.61 |
| MACD | 0.10 | -0.22 |
| Stochastic Oscillator | 65.09 | 6.02 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.